MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Search

Simulations Plus Inc

Suletud

SektorTervishoid

18.94 -1.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.78

Max

19.51

Põhinäitajad

By Trading Economics

Sissetulek

-681K

Müük

17M

P/E

Sektori keskmine

48.528

87.826

Aktsiakasum

-0.034

Dividenditootlus

0.48

Kasumimarginaal

-3.9

Töötajad

212

EBITDA

-79M

-74M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+6.38% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.26%

Järgmine tulemuste avaldamine

8. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

19M

387M

Eelmine avamishind

20.14

Eelmine sulgemishind

18.94

Uudiste sentiment

By Acuity

50%

50%

166 / 372 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. jaan 2026, 23:11 UTC

Tulu

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7. jaan 2026, 22:55 UTC

Suurimad hinnamuutused turgudel

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7. jaan 2026, 21:39 UTC

Suurimad hinnamuutused turgudel

Raytheon Down Following Trump Post Criticizing Company

7. jaan 2026, 20:13 UTC

Suurimad hinnamuutused turgudel

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7. jaan 2026, 20:03 UTC

Suurimad hinnamuutused turgudel

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7. jaan 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. jaan 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7. jaan 2026, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7. jaan 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7. jaan 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7. jaan 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7. jaan 2026, 22:46 UTC

Tulu

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7. jaan 2026, 22:45 UTC

Tulu

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Revolution Medicines Draws Takeover Interest -- 2nd Update

7. jaan 2026, 22:42 UTC

Tulu

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7. jaan 2026, 22:41 UTC

Tulu

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7. jaan 2026, 22:41 UTC

Tulu

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7. jaan 2026, 22:40 UTC

Suurimad hinnamuutused turgudel

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7. jaan 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7. jaan 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7. jaan 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. jaan 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7. jaan 2026, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7. jaan 2026, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7. jaan 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7. jaan 2026, 20:29 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Near Deal for Revolution Medicines -- Update

7. jaan 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7. jaan 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7. jaan 2026, 19:48 UTC

Suurimad hinnamuutused turgudel

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

6.38% tõus

12 kuu keskmine prognoos

Keskmine 20.5 USD  6.38%

Kõrge 25 USD

Madal 16 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

2

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

166 / 372 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat